News
US biotech firm Stealth BioTherapeutics (OTCQB: MITO) is facing renewed uncertainty after the American medicines regulator ...
US pharma giant Merck & Co has started building a $1 billion, 470,000-square-foot biologics center of excellence in ...
US biotech Transneural Therapeutics has named industry veteran Mark Demitrack as its chief research and development officer, ...
A San Francisco-based biopharma company developing a topical protein therapy for dystrophic epidermolysis bullosa (DEB).
Regulus Therapeutics (Nasdaq: RGLS) saw its shares leap 133% to $7.84 in pre-market activity this morning, on the news it has ...
Chicago-based drugmaker AbbVie has announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), ...
Danish drugmaker Novo Nordisk has announced that it is expanding patient access to Wegovy (semaglutide) injection 2.4 mg in ...
Swiss generics and biosimilars major Sandoz (SIX: SDZ) has signed a global collaboration with Shanghai Henlius Biotech (HKEX: ...
California-based Creyon Bio has announced a global licensing and multi-target research collaboration with US pharma major Eli ...
The Russian pharmaceutical market grew up to 814 billion roubles ($10 billion) in the first quarter of 2025, 11% higher ...
In a recent study conducted by Navaneethan and colleagues and published in the International Society of Nephrology, the ...
Swiss generics and biosimilars major Sandoz (SIX: SDZ) today presented its net sales update for the first quarter of 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results